• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Friedreich Ataxia - Pipeline Review, H2 2012 Product Image

Friedreich Ataxia - Pipeline Review, H2 2012

  • Published: October 2012
  • 55 pages
  • Global Markets Direct

Friedreich Ataxia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Friedreich Ataxia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Friedreich Ataxia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Friedreich Ataxia. Friedreich Ataxia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Friedreich Ataxia.
- A review of the Friedreich Ataxia products under development by companies and universities/research institutes READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Friedreich Ataxia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Friedreich Ataxia 8
Friedreich Ataxia Therapeutics under Development by Companies 10
Friedreich Ataxia Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Friedreich Ataxia Therapeutics – Products under Development by Companies 16
Friedreich Ataxia Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Friedreich Ataxia Therapeutics Development 18
ViroPharma Incorporated 18
Repligen Corporation 19
Santhera Pharmaceuticals Holding AG 20
Varinel, Inc. 21
STATegics, Inc. 22
Friedreich Ataxia – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Indole-3-Propionic Acid - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
VAR-10300 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
VAR-10100 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
epoetin alfa - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
idebenone - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
RG-2833 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
pioglitazone hydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Resveratrol - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
STS-E15 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Friedreich Ataxia Therapeutics – Drug Profile Updates 41
Friedreich Ataxia Therapeutics – Discontinued Products 44
Friedreich Ataxia Therapeutics - Dormant Products 45
Friedreich Ataxia – Product Development Milestones 46
Featured News & Press Releases 46
Mar 15, 2012: Repligen Initiates Phase I Clinical Trial Of RG2833 In Patients With Friedreich's Ataxia 46
Apr 12, 2011: Intellect Neurosciences Files Orphan Drug Application In US For OX1 In Friedreich's Ataxia 47
May 24, 2010: Repligen Receives FDA Orphan Drug Designation For RG2833 For Treatment Of Friedreich's Ataxia 47
May 20, 2010: Santhera's MICONOS Trial With Catena/Sovrima in Friedreich's Ataxia Misses Primary Endpoint 48
May 13, 2010: Repligen Files Investigational New Drug Application with FDA for First Drug Targeting The Core Genetic Defect Of Friedreich’s Ataxia 49
Feb 17, 2010: Otonomy Wins FDA Clearance To Initiate Clinical Trial Of OTO-104 Against Menieres Disease 50
Jan 11, 2010: Penwest Pharmaceutical Announces Initiation Of Phase IIa Clinical Trial of A0001 In Patients With Friedreich's Ataxia 50
Nov 02, 2009: Lundbeck Starts Clinical Phase IIa With Lu AA24493 (cEPO) In Friedreich's Ataxia In A Study Also Assessing Efficacy Via Biomarkers 51
May 26, 2009: New Study To Examine Whether Smoking Cessation Drug Varenicline (Chantix) May Benefit Adults With Friedreich’S Ataxia 52
May 19, 2009: Santhera's US Phase III IONIA Trial In Friedreich's Ataxia Misses Primary Endpoint 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables
Number of Products Under Development for Friedreich Ataxia, H2 2012 8
Products under Development for Friedreich Ataxia – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
ViroPharma Incorporated, H2 2012 18
Repligen Corporation, H2 2012 19
Santhera Pharmaceuticals Holding AG, H2 2012 20
Varinel, Inc., H2 2012 21
STATegics, Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Friedreich Ataxia Therapeutics – Drug Profile Updates 41
Friedreich Ataxia Therapeutics – Discontinued Products 44
Friedreich Ataxia Therapeutics – Dormant Products 45

List of Figures
Number of Products under Development for Friedreich Ataxia, H2 2012 8
Products under Development for Friedreich Ataxia – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos